Picture1.jpg
Clearmind Medicine Appoints Distinguished Addiction Experts Professor Wim van den Brink and Professor Gabriele Fischer to Its Scientific Advisory Board
October 14, 2021 08:00 ET | Clearmind Medicine
TORONTO, Ontario, Oct. 14, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Picture1.jpg
Clearmind Medicine Partners With Clinipace to Commence Processes Towards FDA Approval
October 07, 2021 08:00 ET | Clearmind Medicine
Toronto, Ontario, Oct. 07, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0), (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
Rectangle Color logo with background (1).png
Tripsitter.Clinic Launches At-Home Ketamine Therapy Service Across the U.S.
September 01, 2021 11:32 ET | TripSitter.Clinic
AUSTIN, Texas, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Tripsitter Clinic Corp. is pleased to announce that the company is now accepting and seeing patients throughout the states of California,...
87520785_101152591495741_6497961433500745728_o.jpg
Mycotopia Therapies Signs Agreement With Havn Life Sciences For Purchase of Psilocybin SPP
August 25, 2021 08:00 ET | Mycotopia Therapies Inc.
MIAMI, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies, Inc. (OTC Pink: TPIA) (the “Company”), a company focused on psychedelic therapies, announced today it has entered into a Psilocybin...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
August 19, 2021 08:17 ET | InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Ehave acquires License covering G-20 Countries for all Psychedelic use, AI-Powered Telehealth Technology To Capture Physiological Vitals From Vastmindz; Prepares To Run Testing On Dashboard
August 11, 2021 08:30 ET | Ehave
MIAMI, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc., (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today it has...
ehave-logo.png
Ehave Partners with Globally Recognized University to Target Hallucinogen Persisting Perception Disorder (HPPD)
August 04, 2021 08:30 ET | Ehave
MIAMI, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, today announced a...
ehave-logo.png
Hallucinogen Persisting Perception Disorder (HPPD) Research Initiated By Ehave
July 29, 2021 08:30 ET | Ehave
HPPD is a psychiatric disorder characterized by the persisting presence of sensory disturbances, most commonly visual, that resemble those produced by the use of hallucinogenic substances. Ehave...
ehave-logo.png
Ehave Releases Additional Information On Partnership With Cutting Edge Data Provider As It Expands Capabilities
July 13, 2021 08:30 ET | Ehave
MIAMI, July 13, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced a partnership with...
ehave-logo.png
Ehave Hires Institutional Review Board (IRB) As It Solidifies Partnership With Tristar Wellness Launching Ketamine Clinical Trials In Miami
July 09, 2021 09:30 ET | Ehave
MIAMI, July 09, 2021 (GLOBE NEWSWIRE) -- Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today the Company...